Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
about
The AMPK signalling pathway coordinates cell growth, autophagy and metabolismThymidylate synthase expression determines pemetrexed targets and resistance development in tumour cellsRapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer.Cytotoxic autophagy in cancer therapy.The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.Targeting tumour proliferation with a small-molecule inhibitor of AICAR transformylase homodimerizationFolate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors.Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.Metabolomic fingerprint reveals that metformin impairs one-carbon metabolism in a manner similar to the antifolate class of chemotherapy drugs.Differential regulation of autophagy and cell viability by ceramide species.AMP-activated Protein Kinase (AMPK) Control of mTORC1 Is p53- and TSC2-independent in Pemetrexed-treated Carcinoma CellsNovel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cellsBNIP3 is degraded by ULK1-dependent autophagy via MTORC1 and AMPKSorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signalingA marriage of two "Methusalem" drugs for the treatment of psoriasis?: Arguments for a pilot trial with metformin as add-on for methotrexate.The antifolatesPhase I study of pemetrexed with sorafenib in advanced solid tumors.The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer.Targeting autophagy during cancer therapy to improve clinical outcomes.Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.AMP-activated protein kinase activators in diabetic ulcers: from animal studies to Phase II drugs under investigation.PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape.High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy.Metabolomics identifies pyrimidine starvation as the mechanism of 5-aminoimidazole-4-carboxamide-1-β-riboside-induced apoptosis in multiple myeloma cells.Dasatinib modulates sensitivity to pemetrexed in malignant pleural mesothelioma cell lines.[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxidep53 Deletion or Hotspot Mutations Enhance mTORC1 Activity by Altering Lysosomal Dynamics of TSC2 and Rheb.Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling.The promise and challenges of exploiting the proton-coupled folate transporter for selective therapeutic targeting of cancer.Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients.A combined tissue engineered / in silico signature tool for patient stratification in lung cancer.Characterization of a novel AICARFT inhibitor which potently elevates ZMP and has anti-tumor activity in murine models
P2860
Q24616273-59AD1022-01CA-4522-ADAD-52D77D4FE7D9Q28487936-246066C1-D42A-413F-B4CF-80159E54487DQ33572258-AD6BB347-133C-4BBC-9ADA-3193894DB39DQ33907663-8F8D3B9F-DF9E-4948-B097-F394FA6BEF57Q34297931-28892726-FB22-49F9-B367-E30FC3696B3CQ34327238-1A9DBE8C-E2A4-4EE5-8C51-F18237EF1A0FQ34333704-D6869F0C-CF32-4051-8246-FACDD6CE1FCFQ35113327-565CDE34-D4B0-4FD7-A4A2-303BBC9B5C02Q36209145-271A410A-2C5B-4331-8D84-29D53609B89BQ36214943-39C6BD36-084D-4932-B5A6-7CB8C8538058Q36282831-32963DEA-B989-4F08-A616-079F37EE208CQ36467569-F94F7A5E-03DB-41D4-A126-E12D0D4DE760Q36557343-8DA15B62-25DB-4EC2-9001-4C975168582CQ36662352-DA41EEE0-DCDE-4073-B381-FA0841DE1841Q36919811-151761C9-41EE-4518-BCE0-337DDDB96403Q37170305-CE6A8DE8-B63B-48DB-8E72-F294614F35B2Q37183495-31FA80FD-44F9-4350-A867-F0CDAD9C1DA9Q37520649-7033260F-A55F-4785-9E59-5E239B61FB2DQ37663377-A0C5093E-3A27-4284-AAA0-184C87DFB046Q37858077-7F749E4C-7E57-41C9-BF70-4D6A48D78794Q38204673-551D4B65-4624-44FB-9F15-EF9C6642E153Q38214392-BDAF29EE-9424-4A99-AB83-6DE23AF41236Q38721255-4F6AAF96-680B-4AC2-8F5C-1BC3E3B5A042Q38922208-C5354ADC-0176-4583-A7CC-1214E5D97612Q39199511-7D05ADC8-CB9A-435D-B988-1E79CF86A5CBQ39435452-A514A8EC-594B-427C-8C3E-828BB11B9BD1Q39621469-37E85DDD-A246-43C0-8679-42822A1938B0Q39888747-909F71F0-E5F0-46F6-983C-4AC1D425EB85Q42316209-FC35D565-1CF5-46B6-AB16-C9F58DFE6B90Q43084695-247F6D71-6CE5-4741-904D-BC63FCEE8E6EQ47144046-74C35C72-7BFD-4213-909B-CD5DAC4D5107Q50062142-AFD499D5-03B4-4017-9C2D-B3DE90ED35D8Q53564503-2FEA9984-A2C7-4906-81CF-4F0C879BE9FFQ54978277-901CABE0-74C8-4FCE-8FD1-482203F0B417Q58603752-621F6556-CB4F-417F-8287-7BFD3D648891
P2860
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@ast
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@en
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@nl
type
label
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@ast
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@en
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@nl
prefLabel
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@ast
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@en
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@nl
P2860
P1433
P1476
Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas.
@en
P2093
Alexandra C Racanelli
Richard G Moran
P2860
P304
10299-10309
P356
10.1158/0008-5472.CAN-10-1873
P407
P577
2010-12-01T00:00:00Z